Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinomaOA
Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
Yang Zhao;JiaYing Lai;RunBin Liang;MinKe He;Ming Shi
Department of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaHuiDong Senior Middle School, Huidong Huizhou, ChinaDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, ChinaDepartment of Hepatobiliary Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
Hepatocellular carcinomaBarcelona clinic liver cancer stage CSorafenibHepatic arterial infusion chemotherapyOxaliplatin
Hepatocellular carcinomaBarcelona clinic liver cancer stage CSorafenibHepatic arterial infusion chemotherapyOxaliplatin
《介入医学杂志（英文）》 2019 (2)
78-83,6
This work was supported by National Key R&D Program of China (2017YFA0505803),National Natural Science Foundation of China (No.81625017,No.81572385),National Science and Technology Major Project of China (2018ZX10302205).
评论